Xenome adds Cherrington to board
Tuesday, 11 August, 2009
Experienced biotech board jockey, Dr Julie Cherrington, has joined the board of the privately listed Xenome as an independent, non-executive director. The appointment was effective as of August 1.
Cherrington has held numerous posts in Australia and the United States in biotechnology companies, including seats on the boards of ChemGenex and Progen Pharmceuticals.
She is also president of San Diego-based biopharmceutical company, Phenomix Corporation. Prior to her appointment as president, Cherrington served as the executive vice president of research and development at Phenomix. She has also held research positions at SUGEN and Gilead Sciences.
Xenome focuses on discovery and development of peptide-based therapeutics derived from venom. Its lead product is Xen2174, a novel conopeptide analogue for the treatment of moderate to severe pain.
Xenome was profiled in the September/October 2008 issue of Australian Life Scientist.
Heart implant brings hope to refractory angina patients
The coronary sinus reducer is understood to redistribute blood flow within the wall of the heart,...
Researchers genetically engineer snake antivenom
An international team of researchers has used genetic engineering to create so-called...
Common medications linked to adverse breast cancer outcomes
An international study has found concerning evidence about the impact of a range of common...
